Introduction
Accurate risk assessment is pivotal for women at high risk for breast cancer to personalize risk-reduction interventions (1) . In clinical practice, several riskreduction strategies are being employed, ranging from lifestyle changes and chemo-prevention to invasive interventions, such as prophylactic mastectomy and salpingo-oophorectomy (2-6). Although these interventions are efficient in reducing cancer risk (6,7), they are associated with substantial side effects (8,9), and can negatively impact the quality of life (10). However, it currently remains uncertain which level of intervention is indicated for individual women (11), leading to potential over-and under-treatment. Therefore, methods to better determine the likelihood of response to risk-reduction interventions to better guide risk management decisions are urgently needed.
Magnetic resonance imaging (MRI) of the breast allows a three-dimensional assessment of both the anatomic and physiologic activity of breast tissue. In addition, MRI provides insight about the amount of fibroglandular breast tissue (FGT), as well as background parenchymal enhancement (BPE). Thus, FGT and by on October 1, 2017. For personal use only. jnm.snmjournals.org Downloaded from 7 BPE are considered more sensitive predictive and prognostic imaging biomarkers than density assessment with mammography (12-18).
Similar to MRI, positron emission tomography (PET) using the radiotracer 18F-fluoro-deoxy-glucose (18F-FDG) provides insights into the physiologic activity of the normal breast parenchyma through the depiction of tissue glucose metabolism (19) (20) (21) (22) (23) (24) . This 18F-FDG uptake is defined as breast parenchymal uptake (BPU). Thus, it could be that BPU might also serve as an important imaging biomarker in breast cancer.
With the worldwide implementation of hybrid PET/MRI systems or dedicated breast PET systems, there is the potential to simultaneously assess and monitor these imaging biomarkers of breast cancer (19, 25, 26) . To define the value of BPU, BPE, and FGT as imaging biomarkers for breast cancer and utilize these for better guidance of risk management decisions, information about their correlations and reproducibility is needed. However, to date, no such information exists. Therefore, the aim of this study was to quantitatively assess BPU on by on October 1, 2017. For personal use only. jnm.snmjournals.org Downloaded from 8 18F-FDG PET/CT and examine its correlation with BPE and FGT on MRI and age.
Materials and Methods
The institutional review board approved this prospective, single-institution study and retrospective data analysis and all patients gave written, informed consent.
Patients
From 12/2009 to 04/2014, 172 consecutive patients were included in this study. Twenty-eight patients had to be excluded because of incomplete examinations or prior treatment. All patients fulfilled the following inclusion criteria and underwent 18F-FDG PET/CT and MRI: 18 years or older; not pregnant; not breastfeeding; suspicious finding at mammography or breast ultrasonography, i.e., asymmetric density, architectural distortion, breast mass, or microcalcifications (BI-RADS 0, further imaging warranted; 4, suspicious abnormality; 5, highly suggestive for malignancy); no previous treatment; and no contraindications for MRI or MRI contrast agents. In 30 patients, imaging revealed an abnormality in the contralateral breast (BI-RADS 2-5). All suspicious lesions were histopathologically verified by either image-guided or surgical biopsy. Of the 172 patients, 129 (age: 57.9 +/-3.9, range 18-87 years) who 
Imaging
All patients underwent 18F-FDG PET/CT and MRI. Examinations were no longer than six days apart (mean 2.26; range 0-6; same day, n=57, 1 day, n=32, 2 days, n=11, 3 days, n=9, 4 days, n=12, 5 days, n=5, 6 days, n=1).
In all patients, a prone PET/CT dataset over the breasts was acquired using a combined PET/CT in-line system (Biograph 64 TruePoint® PET/CT system, Siemens, Erlangen, Germany), allowing the same patient geometry as with MRI. The whole-body PET/CT system is equipped with a high-resolution 
Data analysis

18F-FDG PET/CT
After image reconstruction, a three-dimensional region of interest (ROI) was carefully drawn on the contralateral normal breast around the glandular breast tissue, as determined by visual inspection on the consequent 4-6 PET/CT scan slices by a breast radiologist under the supervision of a nuclear medicine physician. The nipple and areola area were excluded from ROI placement. From these ROIs, the maximum standardized uptake value (SUVmax) was calculated.
In all patients, BPU SUVmax measurements were repeated by Reader 1 to assess reproducibility.
MRI
In all patients, FGT and BPE of the normal contralateral breast were qualitatively assessed by two independent readers using the revised American Table 1 .
Results
Mean
Correlations of BPU, BPE, FGT, and age for both readers are summarized in the correlation coefficient matrix showing numerical, color-, and size-coded Pearson correlation coefficients (Fig.1) . Correlation coefficients ranged between moderate, i.e., 0.3-0.5 (BPU with age, BPE with FGT; BPE with FGT) and strong, i.e., 0.5-0.7 (age with BPU, BPE, and FGT).
BPU showed a significant moderate direct correlation with BPE (p<0.001, The results of our study demonstrate that BPU, which is the degree of 18F-FDG uptake in the glandular tissues of the normal breast, varies between patients. BPU was directly correlated with both MRI-derived BPE and FGT.
Patient age showed a moderate to strong indirect correlation with all three imaging-derived tissue biomarkers. BPU measurements were highly reproducible, and there was almost perfect inter-and intra-reader agreement for both BPE and FGT with MRI. These findings indicate that BPU may serve as a sensitive predictive and prognostic imaging biomarker for breast cancer prediction, prognosis, and risk assessment.
To our knowledge, this is the first study to examine the correlation of BPU on 18F-FDG PET/CT with BPE and FGT on MRI. We identified a significant direct correlation between BPU and BPE and FGT, which suggests that BPU could also be used as an imaging biomarker for risk assessment, hormonal replacement therapy, or chemo-prevention. Just as the imaging biomarkers BPE and FGT on MRI, BPU can be assessed non-invasively, but a definite benefit of BPU compared to BPE and FGT is that it can be assessed quantitatively and is highly reproducible, which is a prerequisite for a stable and clinically relevant imaging biomarker (32,33).
To date, the correlation of 18F-FDG radiotracer uptake in normal breast parenchyma with BPE has been investigated using solely 18F-FDG positron emission mammography (18F-FDG PEM). In this single retrospective study, Koo et al. assessed the correlation of BPU on 18F-FDG PEM, BPE on CE-MRI, and mammographic breast density (34). Although mean BPU increased from minimal to marked BPE, there was considerable overlap, especially for women with minimal and mild BPE, and mean BPU was not an independent predictor of BPU on PEM. In contrast, in the current study, we found a direct correlation between BPU and BPE. The divergent results might be explained by the fact that, in the study by Koo et al., there was a small sample size, especially for moderate (n=5) and marked BPE (n=5), which may have led to underpowered statistical analyses. Moreover, in contrast to the current study, BPU was assessed using a two-dimensional imaging modality, i.e., 18F-FDG PEM, which could have influenced the results, and thus, limits comparability. In addition, MRIs were not scheduled according to the menstrual cycle, and there is no information on the time-interval between PEM and MRI, which potentially might act as another confounding factor.
Currently, no information exists on the correlation of BPU and FGT on MRI, which is a newly introduced BI-RADS descriptor in the ACR MRI BI-RADS® lexicon. In this first study to examine the correlations between BPU and FGT, we found a direct correlation. This is in agreement with studies that have investigated the correlation of BPU on 18F-FDG PET or PEM and mammographic breast density, which is the equivalent of FGT on MRI. (34-37).
These results further underline the potential of BPU as a valuable imaging biomarker in breast cancer.
An increased mammographic breast density, which is the equivalent of The current study has some limitations. A limitation of our study is the small number of patients with marked BPE. However, this reflects the normal distribution of BPE in the population. Additioanlly, we performed a grouped analysis for patients with greater levels of BPE, i.e moderate and marked, which yielded similar results. In this study, in contrast to BPU, BPE and FGT were assessed qualitatively. However, currently, the ACR BI-RADS lexicon does not recommend quantitative assessment of BPE and FGT, but there was excellent intra-and inter-reader agreement for BPE and FGT. Therefore, the approach in this study seems to be justified. In this study, not all PET/CT and MRI examinations were performed on the same day (range 0-6), which potentially might have had an impact on BPE in a few cases due to the changes in BPE with the menstrual cycle. However, in the majority of cases, the interval between examinations was short (mean 2.26 days), and thus, relevant changes in BPE seem unlikely. In conclusion, the results of our study demonstrate that BPU varies between patients. BPU is directly correlated with both BPE and FGT on MRI.
Patient age shows a strong inverse correlation with all three imaging-derived tissue biomarkers. BPU measurements are highly reproducible, with almost perfect inter-and intra-reader agreement for both BPE and FGT with MRI.
These findings indicate that BPU may serve as a sensitive imaging biomarker for breast cancer prediction, prognosis, and risk assessment. 
